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Neurobiology of Disease

The Fetal Basis of Amyloidogenesis: Exposure to Lead and
Latent Overexpression of Amyloid Precursor Protein and
␤-Amyloid in the Aging Brain
M. Riyaz Basha,1 Wei Wei,1 Saleh A. Bakheet,1 Nathalie Benitez,1 Hasan K. Siddiqi,1 Yuan-Wen Ge,2 Debomoy K. Lahiri,2
and Nasser H. Zawia1
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, and 2Laboratory of Molecular
Neurogenetics, Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202

1

The fetal basis of adult disease (FeBAD) hypothesis states that many adult diseases have a fetal origin. According to FeBAD, injury or
environmental influences occurring at critical periods of organ development could result in “programmatic” changes via alterations in
gene expression or gene imprinting that may result in functional deficits that become apparent later in life. Alzheimer’s disease (AD) is a
progressive neurodegenerative disorder that is characterized by excessive deposits of aggregated ␤-amyloid (A␤) peptides, which are
snippets of the ␤-amyloid precursor protein (APP). The predominately sporadic nature of AD suggests that the environment must play
a role in neurodegeneration. To examine latent responses to an environmental agent, we exposed rodents to lead and monitored the
lifetime expression of the APP gene. We observed that APP mRNA expression was transiently induced in neonates, but exhibited a
delayed overexpression 20 months after exposure to Pb had ceased. This upregulation in APP mRNA expression was commensurate with
a rise in activity of the transcription factor Sp1, one of the regulators of the APP gene. Furthermore, the increase in APP gene expression
in old age was accompanied by an elevation in APP and its amyloidogenic A␤ product. In contrast, APP expression, Sp1 activity, as well
as APP and A␤ protein levels were unresponsive to Pb exposure during old age. These data suggested that environmental influences
occurring during brain development predetermined the expression and regulation of APP later in life, potentially altering the course of
amyloidogenesis.
Key words: Alzheimer; ␤-peptide; CNS; dementia; development; environment; latency; transcription

Introduction
Epidemiological studies have shown that fetal undernutrition,
lower birth weights, and obesity in humans are associated with an
increased risk of death from diabetes, congestive heart failure,
and stroke (Barker et al., 1989; Valdez et al., 1994; Yarbrough et
al., 1998; Ozanne, 2001). The fetal basis of adult disease (FeBAD)
hypothesis states that many adult diseases have a developmental
origin. Thus, the promotion of amyloidogenesis may begin very
early in life. Although it can be speculated that environmental
insults occurring during early growth could impact the ability of
an organ to respond to stress or disease later in life, the molecular
targets that could mediate such delayed or latent effects have not
yet been characterized. It is known that tissues and organs go
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through “critical periods” of development, which coincides with
stages of rapid cell growth in which differential gene expression
plays a major role. It has also been suggested that disturbances
during these critical periods could force the body to adapt and
pool resources and alter programming of the expression of genes
important for normal lifelong physiology (Barker et al., 1989;
Barker, 2002).
The contribution of the environment to disease processes is
increasingly becoming more appreciated. Among the many
chemicals one is exposed to, a few chemicals are of widespread
public concern. The heavy metal Pb is among such chemicals.
The total consumption of Pb in the United States is ⬃1.3 ⫻ 10 6
metric tons (Goyer, 1996). Humans can be exposed to Pb
through paint, glazed earthenware, lead piping solder in food
containers, moonshine whiskey, and automobile battery casing
(Goyer, 1996). Although organic forms of Pb have been removed
from gasoline, inorganic Pb still remains the number one environmental hazard facing human populations today. Furthermore, the aging populations today had been exposed in the past
to much higher levels of environmental Pb.
Developmental exposure to low levels of Pb has long been
known to produce impairments in intellectual functioning and
disturbances in a number of molecular, biochemical, and morphological events (Needleman et al., 1990; Silbergeld, 1992;

824 • J. Neurosci., January 26, 2005 • 25(4):823– 829

Zawia, 2003; Basha et al., 2004). The cognitive impairments by Pb
are believed to be permanent; however, it is not known whether
early exposure to Pb can manifest latent effects that could contribute to neurodegenerative events in old age. Expression of certain genes and the transcriptional apparatus could be involved in
this latent induction. To test this hypothesis, we exposed rodents
during the neonatal period to Pb and monitored the lifetime
expression of the APP gene and the activity of specificity protein
1 (Sp1), a transcription factor involved in the regulation of the
APP gene. APP is a transmembrane protein and its proteolytic
processing generates a 39 – 42 residue peptides referred to as
␤-amyloid (A␤). A␤ peptides are the primary constituents of
amyloid deposits found in the aging brain and have been implicated in the pathogenesis of Alzheimer’s disease (AD) and Down
syndrome by genetic, pathologic, and biochemical evidence
(Selkoe, 2001; Nishimura et al., 2002; Lahiri et al., 2003). Therefore, we also examined APP and A␤ levels in old rat brains developmentally exposed to Pb.

Materials and Methods
Animal exposure. Timed-pregnant Long–Evans hooded rats were obtained from Charles River Laboratory (Bar Harbor, ME) in two batches
over a 2 year period. Twenty-four hours after birth on postnatal day 1
(P1), all the pups were pooled, and new litters consisting of eight or nine
males were randomly selected and placed with each dam. The dams were
divided into two groups, namely, Con and Pb-E. The first group (Con)
received deionized water and was considered the control group. The
second group (Pb-E) was exposed to Pb from P1 through P20. The third
group, Pb-L was exposed to Pb only during senescence (i.e., from 18 to 20
months of age). In each exposure scenario, 200 ppm Pb-acetate (Sigma,
St. Louis, MO) was added to the deionized drinking water of the dams or
the aging animals. We found that tissue Pb levels were comparatively low
at this dose, and no gross morphological or nutritional disturbances were
found in the pups or the aging animals (Zawia et al., 1998; Basha et al.,
2003). Food and water were freely available for all the groups throughout
the study. The animals were housed at constant temperature (21 ⫾ 2°C)
and relative humidity (50 ⫾ 10%) with a 12 h light/dark cycle (7:00 A.M.
to 7:00 P.M.). On selected time points (P5, P50, P350, and P600) the
animals (pups/adults/senescent) were decapitated after exposure to CO2,
and hypothermia and various brain regions were isolated and stored at
⫺80°C for use in the molecular and analytical studies reported here. The
animal exposure protocol and the maintenance of the animal facilities
were regularly monitored by the Institutional Animal Care and Use
Committee.
Nuclear protein extraction. Nuclear proteins were extracted from both
cortical tissue and cultured cells according to the method given by Dignam et al. (1983), with slight modifications. Cells/tissue samples were
homogenized with 1 ml of PBS, pH 7.4, and centrifuged at 2500 ⫻ g for 10
min. The pellets obtained were suspended in 5 vol of buffer A (in mM: 10
HEPES, pH 7.9, 1.5 MgCl2, 0.5 DTT, 0.5 EDTA, and 0.2 PMSF) and
centrifuged at 6000 ⫻ g for 2 min at 4°C. The pellets were resuspended in
3 vol of buffer A and centrifuged at 6000 ⫻ g for 2 min at 4°C. The
resulting pellets were then resuspended in 5 vol of buffer C (20 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM EDTA, 420 mM
NaCl, 20% glycerol, 0.2 mM PMSF, 2 g/ml aprotinin, and 0.5 g/ml
leupeptin) and homogenized with a Polytron homogenizer. The final
suspensions were centrifuged at 12,000 ⫻ g for 10 min at 4°C. The supernatants were transferred to 1.5 ml tubes, snap frozen in an ethanol dry-ice
bath, and then stored at ⫺80°C (Zawia et al., 1998; Basha et al., 2003).
Gel mobility shift assays. Changes in the profiles of the Sp1 transcription factor were studied through electrophoretic mobility shift assay.
Nuclear extracts were derived from the cortical tissues as described
above. Consensus oligonucleotide sequence for Sp1 was obtained from
commercial sources (Promega, Madison, WI) and radiolabeled by 5⬘
labeling procedures. The oligos (1.75 pmol) were incubated with 1 l of
[␥- 32P]ATP (3000 Ci/mmol; PerkinElmer, Boston, MA) and 10 U of T4
polynucleotide kinase (Promega) in a final volume of 10 l for 15 min at
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37°C. The reaction was terminated, and the DNA probe was isolated
through purification with a Sephadex G-25 column. A binding reaction
was set up containing: 5000 –20,000 cpm of the DNA probe (0.1– 0.5 ng),
0.5–2 g of poly dI-dC, 5–20 g of the nuclear extract and binding buffer
[2 mM HEPES, 2.5 mM MgCl2, 2.5 mM KCl, 0.5 mM DTT, 2.5% glycerol,
0.001% NP-40, 50 g/ml BSA, 0.2% protease inhibitor mixture (Sigma),
0.2% ficoll, and 20 ng/ml poly dI-dC]. The binding reaction was performed at room temperature for 15 min. The reaction mix was separated
by 6% polyacrylamide gel electrophoresis. The gel was dried and exposed
to a phosphor screen for 2 h and scanned in the Typhoon Variable Mode
Imager 9410. The resulting scanned gels were analyzed for shifted bands
and quantitated using the Image Quant 5.0 software (Zawia et al., 1998;
Basha et al., 2003).
Macroarray analysis. The Message Hunter macroarray screening system (Genotech, St. Louis, MO) was used to study the simultaneous expression of multiple genes. Blots containing fragments of 15 genes from
various families of transcription factors in variable concentrations (2 and
20 ng), prearranged on nylon membranes, along with actin, GAPDH,
and pUC19 DNA as positive or negative controls, were used. Samples of
brain mRNA from control and Pb-exposed animals were isolated and
reverse-transcribed in the presence of [␣- 32P]deoxy-CTP and hybridized to the gene array organized on the nylon membrane. Each gene on
the membrane was 200-bp-long and contained equimolar amount of
DNA. Sequences corresponding to ⬃35 genes of representative transcription factor families were immobilized on several filters. The filters
were then stringently washed and exposed to x-ray films. The resultant
bands were scanned and quantitated using UVP Epi chemi II Darkroom
software. The array data were collected from two sets of experiments, and
each set consisted of tissue pooled from three animals (Bakheet and
Zawia, 2004).
Total RNA isolation, synthesis of cDNA, and PCR. RNA from various
control and exposed cortical tissues was isolated according to the TRIzol
method (Invitrogen, Carlsbad, CA). The RNA was reverse-transcribed to
obtain cDNAs, catalyzed by SuperScript II RNase H reverse transcriptase
(RT). The RNA/primer mixture containing 50 ng of total RNA, 1 l of 10
mM deoxy-NTP mix, and 1 l of oligo(dT) were incubated at 65°C for 5
min. A reaction mixture containing 10⫻ RT buffer (200 mM Tris-HCl,
pH 8.4, 500 mM KCl), 25 mM MgCl2, 0.1 M DTT, and RNaseOUT recombinant RNase inhibitor was added and incubated at 42°C for 2 min. One
microliter of SuperScript II RT was then added and incubated at 42°C for
50 min. The reaction was terminated at 70°C for 15 min. One microliter
of RNase H was added, and the reaction was incubated for 20 min at
37°C. The final product was stored at ⫺20°C and used in the PCR step.
Primers were designed from the APP gene sequences so that their amplified PCR products include all spliced forms of the messages [sense, GAG
GAG GAG GCC GAG GAG CCC TA (base pairs 788 – 810); antisense,
CTC GGT GCT TGG CTT CCA ACC TC (base pairs 1213–1235)] modified from the method of Smith et al. (1991). Control primers for housekeeping genes such as G3PDH and ␤-actin were obtained commercially.
The general PCR step consisted of the reaction of 1 l of each of the
primers, 2 l of the cDNA strand, and 46 l of PCR Supermix obtained
from Invitrogen. Using a MiniCycler, the reaction was denatured at 94°C
for 2 min and subsequently underwent 28 –30 temperature cycles (94°C
denaturing for 30 s, 55°C annealing for 30 s, and 72°C elongation for
30 s). The reaction was held at 72°C for 5–7 min for a final elongation
period. PCR conditions were varied depending on the primers used. The
final PCR product was analyzed onto a 1% agarose/ethidium bromide gel
by running the gel at 80 V in 0.5⫻ Tris-borate EDTA buffer for ⬃90 min
and scanned in the Typhoon Variable Mode Imager 9410. The resulting
scanned gels were quantitated and analyzed using the Image Quant 5.0
software (Zawia et al., 1998; Basha et al., 2003).
Western blot analysis. Polyclonal antibodies for rabbit APP (Sigma)
were used to probe Western blots. Western blotting and quantitation
procedures were performed as described previously (Atwood et al., 1998;
Nunomura et al., 1999) with slight modifications. The protein samples
(2– 4 g) were subjected to SDS-PAGE, transferred to nitrocellulose
membranes, and probed with a polyclonal antibody that recognizes rodent APP [N-terminal antibody (Sigma) developed in rabbit using a
synthetic peptide NVQNGKWDSDPSGTK corresponding to the
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N-terminal region of human APP695 (46 – 60 aa), conjugated to KLH as
the epitope]. The blots were incubated with anti-rabbit horseradish peroxidase, the chemiluminescent signal was captured using Kodak Image
Station, and the images were analyzed and quantified.
Metal analysis. On P20 (completion of early exposure) and at 20
months of age (completion of late exposure), the animals from all the
three groups were used to determine the levels of Pb in the blood and
brain. The metal analysis was performed following the method described
previously (Smith et al., 1998; Basha et al., 2003). Animals were deeply
anesthetized, and blood was collected using a sterile syringe through
cardiac puncture. For the collection of brain tissue, animals were perfused with sterile saline, the brains were excised, and cortical tissue from
the brains was isolated. Samples were pooled from three or four animals,
and three to five sample determinations were made for each exposure
condition. Tissue and blood samples were analyzed by Rhode Island
Analytical Laboratory (Warwick, RI), using atomic absorption spectroscopy following EPA approved methodology.
Cell culture. Pheochromocytoma (PC12) cells ( American Type Culture Collection, Manassas, VA) were maintained under conditions of 5%
CO2 and 37°C. Cells were grown in DMEM (Hyclone, Logan, UT) supplemented to a final concentration with 10% fetal bovine serum (Hyclone), 5% horse serum (Hyclone), and 1% penicillin–streptomycin solution (Sigma).
Transfection and responsiveness of APP promoters. PC12 cells were
plated for 48 h, and the transfection mixture (100 l) containing vectors
suspended in Lipofectamine 2000 reagent (Invitrogen) was added in the
wells. Cells were transfected with plasmid vectors (pGL3) containing the
human APP promoter. pRL-TK, a plasmid construct driven by the herpes simplex virus thymidine kinase promoter, was cotransfected as a
negative control. In some experiments basic pGL3 that lacks any promoter was transfected to serve as a background control. Twenty-four
hours after transfection, a 400 l medium containing 0.1 M of Pb was
added. Cells were harvested using Passive Lysis Buffer (Promega) at 48 h
after exposure.
Silencing of the Sp1 gene using small interfering RNA. For small interfering RNA (siRNA), sense, antisense, and T7 promoter oiligonucleotides were synthesized by Invitrogen. The synthetic oligos had the following sequences: T7 promoter, 5⬘-TAATACGACTCACTATAG-3⬘; sense,
5⬘-ATGATCGTGCCTGCCTGAGAGCTATAGTGAGTCGTATTA-3⬘;
antisense, 5⬘-CAGCTCTCAGGCAGGCACGATCTATAGTGAGTCGTATTA-3⬘. One nanomole of T7 and sense/antisense were annealed in
50 l of Tris EDTA buffer, heated at 95°C for 5 min to obtain doublestranded DNA (dsDNA). In vitro transcription was performed using the
AmpliScribe T7 High Yield Transcription kit (Epicenter Technologies,
Madison, WI). Both transcription reactions of sense and antisense were
mixed and heated at 95°C for 5 min and then cooled down. After purification of siRNA with 0.2 M sodium acetate and 70% ethanol, the siRNA
was reconstituted with water that it is ready for transfection into cells.
The extent of silencing the Sp1 gene was validated using the luciferase
assay described below.
Measurement of reporter gene activity. For the luciferase assay, 10 l of
homogenized lysates were analyzed using Dual-Luciferase Reporter Assay System (Promega) in an LB 96 V microplate luminometer. The APP
promoter constructed on pGL3 [APP(⫹)], pGL3-Basic [APP(⫺)], and
pRL-TK vectors were used. Their reporter genes following translation
into enzymes result in bioluminescent products during the analysis. The
APP(⫹) and APP(⫺) vectors contain firefly luciferase luc⫹ as the reporter gene, which is quantifiable by the luciferase assay reagent. The
pRL-TK has the renilla luciferase reporter gene (rluc) to serve as a control
for transfection efficiency. The renilla luciferase gene product has different substrate specificity from firefly luciferase. Applying specific substrates as described by the manufacturer can distinguish between the
activities of both enzymes. Thus, the same assay records both firefly and
renilla luciferase activities. The ratio of firefly luminescence signal for
APP(⫹) and APP(⫺) over renilla luminescence signal (pRL-TK) in samples gives APP(⫹) and APP(⫺) relative activities.
Amyloid ␤ assay. The levels of amyloid ␤-40 were measured using the
IBL assay kit (IBL, Gunma, Japan). This kit is a solid phase sandwich
ELISA that uses two kinds of highly specific antibodies. This kit measures
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both soluble and insoluble A␤ levels in tissue and serum according to the
information provided by the suppliers. The assay conditions were followed according to the method described by Morishima-Kawashima et
al. (2000), with slight modifications as suggested by the manufacturers.
Brain tissue extracts (test samples) were prepared following the
guanidine-HCl extraction method. Brain tissue was homogenized in
Tris-saline (TS) (50 mM Tris-HCl buffer, pH 7.4, 150 mM NaCl, 1 g/ml
N-␣-p-tosyl-L-lysine chloromethyl ketone, 1 g/ml antipain, 0.5 mM diisopropyl fluorophosphates, 0.5 mM PMSF, and 0.1% protease inhibitor
mixture) and centrifuged at 100,000 ⫻ g for 20 min at 4°C. The pellet was
resuspended in 4 vol of TS and centrifuged at 70,000 ⫻ g for 20 min at
4°C. The resultant pellet was dissolved in 500 l of 6 M guanidine-HCl (in
50 mM Tris buffer, pH 7.6), incubated at room temperature for 30 min
and centrifuged at 70,000 ⫻ g for 20 min at 4°C. The resultant supernatant was collected and diluted by EIA buffer (supplied with the kit) to 12
times to reduce the guanidine-HCl concentration in the samples. The test
samples were aliquoted and stored in a freezer at ⫺80°C. The protein
content was estimated using BCA reagent, and the test samples were
prepared with 200 g of protein in 100 l using EIA buffer to adjust the
volume. The test samples and the standards were added to the 96 well
plate [precoated with anti-human A␤ (35– 40) (1A10) mouse IgG monoclonal antibody] and incubated overnight at 4°C. After several washes
with EIA wash buffer, 100 l of labeled antibody was added to each well
(except the wells corresponding to reagent blanks) and incubated at 4°C
for 1 h. After a thorough wash, 100 l of TMB buffer was added to each
well and incubated in the dark (shielded) for 30 min at room temperature. The reaction was stopped by adding 100 l of 1N H2SO4, and the
readings were taken at 450 nm. The levels of A␤ in the test samples were
calculated by incorporating the unknown values into the standard curve
obtained in the assay.
Statistical treatment. Data were analyzed by two-way ANOVA followed
by a Duncan’s post hoc test to compare the effects among various treatments; values marked with an asterisk are significantly different from
their corresponding controls ( p ⬍ 0.05). The relationship between APP
mRNA expression and Sp1 DNA-binding was analyzed using Spearman
and Pearson correlation analysis using SAS 9.1 (Raleigh, NC).

Results
The promotion of amyloidogenesis may begin very early in life by
interference in the processes that determine the level of responsiveness of the APP gene. The data reported below monitored the
expression of the APP mRNA, the activity of Sp1, APP, and A␤
levels in developmentally exposed animals as well as in animals
exposed during old age.
Exposure to Pb and latent expression of the APP mRNA
To determine whether developmental exposure to Pb resulted in
long-term alterations in the expression of APP, we examined the
lifelong expression of the APP gene. We also monitored the concurrent expression of housekeeping genes. We found that exposure to Pb during the postnatal period resulted in a transient
increase in APP mRNA expression during the first month after
birth followed by a return to basal levels by 1 year, and a subsequent rise in APP expression again at 20 months of age (Fig. 1).
␤-actin mRNA levels remained unchanged by age or Pb exposure
during the same period (Fig. 1), as well as those of G3PDH (data
not shown). Whereas both blood (46.43 ⫾ 1.95 g/dl) and tissue
(0.41 ⫾ 0.04 g/g) levels of Pb were increased during developmental exposure to Pb, both blood and tissue levels of Pb were at
background levels in the neonatally exposed old animals. There
were also no significant changes in the body weights of Pbexposed animals (control, 701.67 ⫾ 16.02 g; Pb-E, 684 ⫾ 25.46 g),
and the survival rate of the exposed group was identical to that of
the control group to 20 months of age.
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Figure 1. Lifetime changes in APP695 and ␤-actin mRNA expression in the cortex. Data
shown are derived from two cohorts of animals separated in time by 1 year. The bar in the figure
indicates the neonatal period of lactational exposure to Pb. Each data point represents the
mean ⫾ SEM for four to six animals. Data were analyzed by two-way ANOVA followed by
a Duncan’s post hoc test to compare the effects among various treatments; values marked
with an asterisk are significantly different from their corresponding controls ( p ⬍ 0.05).

mRNA profiling of transcription factors and
Sp1 DNA-binding
The regulatory portion of the APP gene is a GC-rich region,
which lacks a TATA box and contains consensus sites for several
transcription factors (Salbuam et al., 1988; La Fauci et al., 1989).
To determine whether any of these transcription factors was
prominently altered by Pb exposure, we conducted a macroarray
screen of a series of transcription factors on postnatal day 5, the
age of highest changes in APP expression. We found that Sp1
expression exhibited a high level of induction after Pb exposure
(Fig. 2a). Consequently, we monitored the lifelong profiles of Sp1
DNA-binding in the cortex of control and Pb-exposed animals
and found that exposure to Pb resulted in a premature peak of
Sp1 DNA-binding in the early postnatal period and returned to
basal levels weeks later. Commensurate with APP expression, Sp1
DNA-binding also exhibited a startling rise in activity, 20 months
after Pb exposure had ceased (Fig. 2b).
We performed correlation analysis to determine whether a
relationship existed between APP mRNA expression and Sp1
DNA-binding at various time points. We found an overall statistical correlation between APP expression and Sp1 activity (Spearman correlation coefficient, 0.8); this statistical correlation became higher when one of the time points (P5) was dropped from
the analysis (Pearson correlation coefficient, 0.98). To establish a
direct biological link between APP and Sp1, we conducted cell
culture studies involving the APP promoter and Sp1 presented
below.
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Figure 2. mRNA profiling of transcription factors after developmental exposure to Pb and
lifetime changes in Sp1 DNA-binding in the cortices of control and Pb-exposed animals. a,
mRNA profiling. Cortical total RNA was isolated from P5 rats and used to probe cDNA arrays of
transcription factors: AR, androgen receptor; ATF-4, activating transcription factor-4; c-fos,
c-jun, c-myc, oncogenes; Creb-1, cAMP-responsive element-binding protein-1; E2F-2,
ubiquitin-conjugating enzyme F-2; ER, estrogen receptor; Et, erythroblastosis virus oncogene
homology; GR, glucocorticoid receptor; HMG, high-mobility group protein; NFB, nuclear factor
B; Oct 1, octamer transcription factor 1; p53, phosphoprotein 53; PR, progesterone receptor;
RAR, retinoic acid receptor [related factors: retinoid orphan receptor (ROR), retinoid X receptor
(RXR)]; Stat, signal transducer and activator of transcription; VDR, vitamin D3 receptor. The
array data shown were derived from two sets of experiments, and each set consisted of tissue
pooled from three animals. b, Sp1 DNA-binding. Nuclear extracts were prepared from controls
and animals exposed as indicated by the bar in the figure. Sp1 DNA-binding was analyzed using
gel mobility shift assays. Sp1 DNA-binding data shown are derived from two cohorts of animals
separated in time by 1 year; each data point represents the mean ⫾ SEM for four to six animals.
Data were analyzed by two-way ANOVA followed by a Duncan’s post hoc test to compare the
effects among various treatments. Values marked with an asterisk are significantly different
from their corresponding controls ( p ⬍ 0.05).

The APP promoter, Pb, and Sp1 siRNA
In vivo experiments have shown that exposure to Pb increases the
expression of the APP gene and the activity of Sp1; however, it is
uncertain whether Sp1 was responsible for the changes in APP
expression and whether Pb disturbed the expression of the APP
gene through alterations in Sp1 activity. Therefore, we conducted
independent cell culture experiments to test the responsiveness of
the human APP promoter to Pb exposure and the dependence of
the APP promoter on Sp1 activity. We transfected PC12 cells with
a 1.2 kb human APP promoter (⫺1100/⫹104, ⫹1 being the transcription start site) (Lahiri and Robakis, 1991) linked to a luciferase reporter gene. We found that the APP promoter was active
in these cells and that Pb (0.1 M, determined from a range of
doses) stimulated promoter activity in a delayed manner (Fig.
3a). Pb-induced promoter activity was also accompanied by an
increase in Sp1-DNA binding (Fig. 3a, see inset), and these re-
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Figure 3. Human APP promoter responsiveness after exposure to Pb and silencing of the Sp1
gene using siRNA in PC12 cells. a, Responsiveness of the APP promoter and Sp1 DNA-binding to
Pb exposure. Con, Control. b, Silencing of the Sp1 gene. Cells were incubated in the presence or
absence of Pb (0.1 M) or siRNA (to knock out the Sp1 gene) and harvested to determine
reporter gene activity or Sp1 DNA-binding. APP promoter activity plotted above is the ratio of
activity of cells that contain pGL3 with the APP promoter versus cells transfected with pGL3
minus the APP promoter. Both cells contain the negative pRLTK vector. Promoter values shown
are the means ⫾ SEM of five to seven determinations. Data were analyzed by two-way ANOVA
followed by a Duncan’s post hoc test to compare the effects among various treatments; values
marked with an asterisk are significantly different from their corresponding controls ( p ⬍ 0.05).

sponses were selective for Pb (Ba or Hg had no effect; data not
shown). To further confirm the connection between Sp1 and
APP gene expression, we knocked out the expression of the Sp1
gene in an effort to deplete Sp1 levels using siRNA technology.
Silencing the Sp1 gene resulted in a 75% decrease in the responsiveness of the APP promoter (Fig. 3b).
Effect of Pb exposure during old age on APP and A␤ Levels
To examine whether APP mRNA expression and Sp1 DNAbinding are responsive to Pb exposure during old age, we compared the levels of APP mRNA, Sp1 DNA-binding, APP, and A␤
levels in aged animals exposed to Pb from 18 to 20 months of age
(Fig. 4). Exposure of naive animals during old age had no significant effect on APP mRNA levels, Sp1 DNA-binding, APP, and
A␤ levels (Fig. 4), although Pb concentrations in the blood and
cortex of these animals were significantly elevated (blood Pb ⫽
60.1 ⫾ 15.4 g/dl, and tissue Pb ⫽ 0.32 ⫾ 0.03 g/g). In contrast,
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Figure 4. Unresponsiveness of APP expression, Sp1 DNA-binding, APP and A␤ formation to
Pb exposure in old age. Brain cortices were obtained from control 20-month-old animals and
those directly exposed to 200 ppm of Pb-acetate as follows: control (Con, unexposed), Pb-E
(exposed from P1 to P20), and Pb-L (exposed from 18 to 20 months of age). These tissues were
used to analyze the mRNA expression of APP, ␤-actin (RT-PCR), Sp1 DNA-binding (gel shift),
APP protein levels (Western blot), and A␤ activity (ELISA). Data shown are derived from two
cohorts of animals separated in time by 1 year; each data point represents the mean ⫾ SEM for
four to six animals. Data were analyzed by two-way ANOVA followed by a Duncan’s post hoc test
to compare the effects among various treatments; values marked with an asterisk are significantly different from their corresponding controls ( p ⬍ 0.05).

animals developmentally exposed to Pb exhibited an elevation in
APP mRNA, Sp1 DNA-binding, APP and A␤ levels.

Discussion
Developmental exposure to some environmental agents has been
shown to remain “silent” for a long period of time without any
overt manifestations. Behavioral studies after developmental exposure to environmental agents such as methylmercury (Rice,
1989), methylazoxymethanol (Lee and Rabe, 1992), and triethyltin (Barone et al., 1995) have provided evidence that latent neurotoxicity occurs in adult animals. More recently, developmental
exposure to pesticides has been shown to result in a loss of nigral
dopamine neurons and a decrease in dopamine content, 9
months later (Thiruchelvam et al., 2002; Reeves et al., 2003).
These data suggest that behavioral and neurodegenerative outcomes later in life can be influenced by developmental exposure
to environmental agents.
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Transcriptional events in the brain are selectively susceptible
to environmental influences, and their disturbance may result in
perturbations in the regulation of gene expression. Although
short-term disturbances to transcriptional processes can occur
during any period of life, perturbations of the transcriptional
apparatus in the brain during development may result in permanent reprogramming and alterations in the requirements for gene
expression. The selective changes in APP gene expression occurring during development are transient and a direct result of concurrent Pb exposure; however, the delayed overexpression of APP
in old age, long after Pb exposure has ceased, suggests that developmental exposure to Pb had reprogrammed the responsiveness
of the APP gene. This is also supported by the observation that the
late rise in APP mRNA expression at 20 months of age happened
when both blood and tissue concentrations of Pb in these old
animals were at background levels, thus ruling out the possibility
that Pb is stored in bones, and leaches out, during old age, to
stimulate the upregulation in APP mRNA expression. If we extrapolate the blood Pb levels we found in these animals (control
and Pb-E) at 20 months of age (⬍2 g/dl) to humans, these levels
are well below the 10 g/dl safety level for blood Pb set for humans by the Centers for Disease Control and Prevention (1991).
When we exposed old animals to 200 ppm Pb in their drinking
water for 3 months, we found 40 – 60 g/dl of Pb in their blood.
At least one in 20 children in the United States today have blood
Pb levels ⬎10 g/dl (Pirkle et al., 1998).
The lifelong lag between initial exposure and the delayed elevations in gene expression suggests that the regulatory apparatus
of the APP gene may have been altered by developmental Pb
exposure, rendering the gene more responsive to endogenous
stimuli that appear during old age. Changes in the gene expression are mediated through intercellular and/or intracellular signaling pathways that are finally transmitted through the action of
transcription factors. Because the APP gene could be activated by
several transcription factors, it was important to identify the factor most responsible for Pb-induced changes in the APP gene
expression. We screened transcription factors (TFs) that are
“constitutive” and those, whose activation is “conditional” (i.e.,
dependent on some signaling event).
We found changes in the signal-dependent TFs such as the
steroid receptor superfamily (glucocorticoid receptor, estrogen
receptor, progesterone receptor, retinoid X receptor, retinoic
acid receptor, etc.), development-specific factors [specificity protein 1 (Sp1), octamer transcription factor-1], those respondent to
internal signals (phosphoprotein 53), and those linked to cellsurface receptors (cAMP-responsive element-binding protein,
activator protein-1, nuclear factor B, signal transducer and activator of transcription, etc.). Although changes in expression
levels of most of these TFs were small, it was interesting to observe
that the steroid receptor superfamily exhibited a downregulation
trend. The screening analysis revealed Sp1 to be the most highly
expressed TF after Pb exposure, and the DNA-binding studies
showed that the lifelong changes in Sp1 activity were similar to
those of APP. Sp1 is one of the transcription factors that can
promote the production of APP mRNA (Pollwein et al., 1992;
Querfurth et al., 1999), and Sp1 DNA-binding has been shown to
be highly responsive to the presence of heavy metals such as Pb
(Zawia et al., 1998; Basha et al., 2003).
The lifelong profiles of both APP expression and Sp1 DNAbinding do not exactly mirror each other; however, their similar
responses to Pb exposure during early and late life suggested that
they may be linked. The responsiveness of the human APP promoter to Pb exposure and the ability of Sp1 siRNA to dampen

Basha et al. • Developmental Origin of Amyloidogenesis

such responsiveness strongly suggest that Pb-induced changes in
APP expression are mediated via a mechanism that involves Sp1
(Fig. 3).
Although both APP gene expression and Sp1 activity were
responsive to Pb exposure during brain development or in cells
actively growing in vitro, the delayed changes in both APP and
Sp1 DNA-binding in animals previously exposed to Pb required
additional examination. Furthermore, it was important to know
whether both APP and Sp1 are responsive to Pb exposure during
old age. Interestingly we found that both the APP gene and the
transcription factor that regulates it were not affected by Pb exposure during old age (Fig. 4). This lack of responsiveness of these
molecular markers persisted in the face of brain tissue Pb concentrations that were high, and the animals were directly exposed for
3 months. This affirmed that the latent expression of APP mRNA
and the concurrent rise in Sp1 DNA-binding in old animals was a
programmed event that was set in motion by exposure to Pb in
early life.
Changes in transcriptional events may not be quite important
unless such transcriptional alterations are translated into products that play a role in physiological and pathological processes.
Therefore we examined the levels of APP and its amyloidogenic
A␤ product in old animals. Consistent with the changes in APP
gene expression, latent elevation in both APP and A␤ levels occurred. This suggested that the “reprogramming” of gene expression after developmental Pb exposure had a significant impact on
the functional and pathological events of old age. Furthermore,
recent immunohistochemical data from our lab confirm that Sp1
and APP are colocalized to the same cells in the brain, and the
areas surrounding these cells are also abundant in A␤ levels
(N. H. Zaiwa, B. Brock, K. Dipalma, W. Wei, M. R. Basha, unpublished data). The elevations in APP and the subsequent increase in A␤ peptide, a hallmark of Alzhemier’s pathology, could
influence the course of neurodegeneration in these aging rodents.
The relationship between Sp1, APP, and A␤ in Pb exposed
animals is strongly supported by recent molecular and cell culture studies. In addition to APP, another important protein
closely involved in AD amyloidogenesis is BACE (␤-APP cleaving
enzyme). Indeed, the BACE gene promoter has been shown recently to contain a functional Sp1 site (Ge et al., 2004). Furthermore, overexpression of Sp1 in transfected cells elevates APP
thereby generating higher A␤ levels (Christensen et al., 2004).
Therefore, the promotion of amyloidogenesis may begin very
early in life by interference in the processes that determine the
level of responsiveness of the APP gene. It is unclear why APP
mRNA expression, Sp1 DNA-binding, and de novo synthesis of
APP are resistant to Pb exposure during old age; however, this
lack of responsiveness cannot be attributed to the inability of Pb
to enter the brain, but rather to permissive programming which is
established during development.
The findings of this study raise fundamental biological and
toxicological questions. Among these are: (1) How is an environmental insult maintained for the life of an organism after the
damaging agent had long disappeared? (2) What are the cellular
targets that sustain or retain such perturbations? (3) Why does
such an alteration remain “silent” for a period of time, and what
precipitates its manifestations later in life? and (4) Is this property
unique to the nervous system?
To answer some of these questions, one must deal with the
latency of the response to Pb exposure and the ability of these
molecular markers to register the passage of time. The latent
responses reported here are probably unique to the nervous system and a few other tissues. Because cells in most tissues turn
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over, and proteins are in a continual cycle of synthesis and degradation, the molecular targets that would store and transmit this
information would have to reside in the genome of terminally
differentiated cells. Furthermore, for the damage to persist on the
structure of the DNA, the perturbation has to escape recognition
of DNA repair enzymes. Thus, it is probable that the environmental insult interfered with epigenetic phenomena such as:
DNA methylation patterns, histone deacetylation, and chromatin restructuring. Errors in some of these processes are not subject
to repair because they are not viewed as damage by DNA repair
pathways. Therefore, one interpretation of these data are that Pb
had permanently interfered with the programmatic settings of
the regulation of the APP gene. These settings are established
during development and are critical for the responsiveness of the
gene regulatory apparatus in the adult. Finally, these data suggest
that developmental exposure to Pb exhibits latent effects on the
expression of genes that are known to be involved in neurodegenerative processes during old age. These developmental events may
influence the course of neurodegenerative changes later in life.
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